Structure Therapeutics Inc ADR (GPCR)
Structure Therapeutics Inc. ADR is a depositary receipt listed on NASDAQ that represents the company’s common stock. The underlying issuer is a clinical-stage global biopharmaceutical company focused on developing oral small-molecule medicines for chronic diseases with unmet medical needs, primarily in the United States. Its lead candidate, GSBR-1290, is an oral biased small-molecule glucagon-like peptide-1 receptor agonist being evaluated in two phase 2 trials for obesity, overweight, and related conditions. The pipeline also includes ACCG-2671 and ACCG-3535, an oral small-molecule amylin receptor agonist in phase 1 testing for obesity, as well as ANPA-0073 and LTSE-2578, which is being studied for idiopathic pulmonary fibrosis. Additional programs include research aimed at GIPR and GCGR modulation. The company was formerly known as ShouTi Inc. and was incorporated in 2016. It is headquartered in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GPCR
|
$41.40
|
-13.4% Downside
|
Fair
|
$104.59
|
118.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-20.0x
|
2.4x
|
—
|
3.339 B
|
1.96 B
|
0.2%
|
77.3%
|
33.0
|
—
|
93.5%
|
